Prognosis Benefit 1 Benefit 2
5 yr CVD risk (non-fatal and fatal) CVD events prevented per 100 treated for 5 yrs** NNT for 5 years**
> 30% > 10 per 100 < 10 Suggested starting point for discussion with patient about drug treatment
25-30% 9 per 100 11
20-25% 7.5 per 100 13
15-20% 6 per 100 16
10-15% 4 per 100 25 <<
5-10% 2.5 per 100 40
2.5-5% 1.25 per 100 80
<2.5% < 0.8 per 100 > 120

* cells with this marker indicate that in patients with very high levels of cholesterol (> about 8.5-9 mmol/L) or blood pressure (> about 170 / 100 mmHg), the risk equations may underestimate the true risk. Therefore it is recommended that treatment be considered at lower absolute CVD risks than in other patients.
** assumes BP reduction of about 12 / 6 mmHg in patients with BP > 140-150 / 90, or cholesterol reduction of about 20% in patients with total cholesterol > 5.0-5.5 mmol/L, produces an approximate 30% reduction in CVD risk, whatever the pre-treatment absolute risk.

Prognosis	Benefit 1	Benefit 2
5 yr CVD risk (non-fatal and fatal)	CVD events prevented per 100 treated for 5 yrs**	NNT for 5 years**
> 30%	> 10 per 100	< 10		Suggested starting point for discussion with patient about drug treatment
25-30%	9 per 100	11
20-25%	7.5 per 100	13
15-20%	6 per 100	16
10-15%	4 per 100	25	<<
5-10%	2.5 per 100	40
2.5-5%	1.25 per 100	80
<2.5%	< 0.8 per 100	> 120

*	cells with this marker indicate that in patients with very high levels of cholesterol (> about 8.5-9 mmol/L) or blood pressure (> about 170 / 100 mmHg), the risk equations may underestimate the true risk. Therefore it is recommended that treatment be considered at lower absolute CVD risks than in other patients.
**	assumes BP reduction of about 12 / 6 mmHg in patients with BP > 140-150 / 90, or cholesterol reduction of about 20% in patients with total cholesterol > 5.0-5.5 mmol/L, produces an approximate 30% reduction in CVD risk, whatever the pre-treatment absolute risk.